Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444361 | 0.99 | MEN1 (0.42) | MEN1KMT2AHRH3GAACHRNB2 | |
| SCHEMBL4444695 | 0.94 | MEN1 (0.44) | MEN1KMT2AHRH3GAACHRNB2 | |
| SCHEMBL4438944 | 0.93 | HRH3 (0.43) | MEN1KMT2AHRH3ALDH1A1HRH2 | |
| SCHEMBL4434546 | 0.93 | MEN1 (0.43) | MEN1KMT2AHRH3GAACHRNB2 | |
| SCHEMBL4442132 | 0.87 | MEN1 (0.43) | MEN1KMT2AHRH3GAAALDH1A1 | |
| SCHEMBL3442554 | 0.86 | MEN1 (0.43) | MEN1KMT2AGAACHRNB2CHRNA4 | |
| SCHEMBL4292487 | 0.85 | NAMPT (0.45) | GAAEPHX2LMNA | |
| SCHEMBL4299210 | 0.85 | NAMPT (0.44) | GAAEPHX2LMNA | |
| SCHEMBL708425 | 0.82 | MEN1 (0.45) | MEN1KMT2AHRH3ALDH1A1OPRM1 | |
| SCHEMBL2333396 | 0.82 | CHRNB2 (0.46) | MEN1KMT2AHRH3GAACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | MEN1 2417/4885KMT2A 2533/4885HRH3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.